Johns Hopkins Bloomberg School of Public Health: The INFO Project

Your knowledge-sharing resource on family planning and reproductive health

Shopping Basket

Quick Links

Main Navigation:

About the
INFO Project -

Publications -

Tools &
Services -

Best
Practices -

Knowledge
Management -

Networks &
Communities -

Browse
Topics -

Search Web Site -

The Pop Reporter®

Current Issue

– Events – Archives – Subscribe – Modify Profile – The Pop Reporter en Español (Spanish)

E-mail this item from The Pop Reporter

Fields marked with an asterisk (*) are required. Your information is kept confidential.

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: A phase II randomised controlled trial (2003-07-28)

Separate multiple e-mail addresses with a comma (,)

* To E-mail Address:
* Your E-mail Address:
Subject: The Pop Reporter - Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: A phase II randomised controlled trial (2003-07-28)
Message: I thought you might be interested in this article. The information entered on this page will not be used to send unsolicited email and will not be sold to a 3rd party. Security and Privacy Policy

Disclaimer: The information provided on this web site is not official U.S. Government information and does not represent the views or positions of the U.S. Agency for International Development, the U.S. Government or The Johns Hopkins University.